Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Next Science's Debt-to-EBITDA or its related term are showing as below:
NXSCF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.77 Med: -0.05 Max: -0.02
Current: -0.77
During the past 7 years, the highest Debt-to-EBITDA Ratio of Next Science was -0.02. The lowest was -0.77. And the median was -0.05.
NXSCF's Debt-to-EBITDA is not ranked
in the Drug Manufacturers industry.
Industry Median: 1.58
vs NXSCF: -0.77
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Next Science Debt-to-EBITDA Related Terms
Next Science Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Next Science's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NXSCF vs GCAN, PTPI, GRPS: Debt-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Next Science's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Next Science Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Next Science's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Next Science's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Jun. 2025) EBITDA data.
Next Science (NXSCF) has a Debt-to-EBITDA of -0.84 as of Jun. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Next Science.
Is Next Science's Debt-to-EBITDA too high?
Next Science's current Debt-to-EBITDA is -0.84.
How does Next Science's Debt-to-EBITDA compare to GCAN and PTPI?
Next Science's Debt-to-EBITDA of -0.84 can be compared against companies in the Drug Manufacturers industry. The industry median Debt-to-EBITDA is 1.58. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.58, based on 685 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Next Science. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Next Science's current Debt-to-EBITDA is -0.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Next Science stock overvalued right now?
Next Science (NXSCF) has a current Debt-to-EBITDA of -0.84. The stock's GF Value™ is $0.26, compared to a current price of $0.00 — trading 99.6% below its estimated fair value. The current Debt-to-EBITDA is -0.84. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Next Science (NXSCF), the current Debt-to-EBITDA is -0.84 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Next Science Ltd is a medical technology company. It is engaged in the development and commercialization of its proprietary Xbio technology to reduce the impact of biofilm-based infections in human health. Xbio is a non-toxic technology with efficacy in eradicating both biofilm-based and free-floating bacteria. Its products include Bactisure, XEPERIENCE and BLASTX. The company derives revenue from North America, New Zealand, and Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NXSCF has been successfully added to your 
